BioLineRx (BLRX) Q3 2025 Earnings Call Summary

1Key Financial Results and Metrics

Total Revenues:: $0.4 million, primarily from royalties on APHEXDA sales.

Net Loss:: $1 million, a significant decrease from $5.8 million in Q3 2024.

Cash Position:: $25.2 million as of September 30, 2025, sufficient to fund operations into the first half of 2027.

R&D Expenses:: $1.7 million, down from $2.6 million in Q3 2024, due to lower costs associated with motixafortide and reduced headcount.

Sales and Marketing Expenses:: No expenses reported in Q3 2025, compared to $5.5 million in Q3 2024, following the shutdown of U.S. commercial operations.

2Strategic Updates and Business Highlights

Joint Venture (JV) with Hemispherian:: Established to develop GLIX1, a novel oral small molecule targeting glioblastoma and other cancers. BioLineRx holds a 40% stake in the JV, with potential to increase to 70%.

GLIX1 Development:: First-in-human Phase I/IIa trial for glioblastoma expected to start in Q1 2026, with data anticipated in H1 2027. The drug has shown promising preclinical results and is designed to cross the blood-brain barrier.

Patent Protection:: Received a notice of allowance for a key patent covering GLIX1, extending protection until 2040 with potential extensions.

Motixafortide in Pancreatic Cancer:: Ongoing Phase IIb trial (CheMo4METPANC) evaluating motixafortide in combination with PD-1 inhibitor and standard chemotherapy.

3Forward Guidance and Outlook

Clinical Trials:: Anticipation of early data from GLIX1's Phase I trial in 2027, with updates expected at conferences.

Market Potential:: The addressable market for glioblastoma is estimated at over $3.7 billion in the U.S. and Europe, with a significant unmet need for effective treatments.

Long-term Strategy:: Focus on expanding GLIX1's applications to other cancer types once safety and dosing are established.

4Bad News, Challenges, or Points of Concern

Revenue Decline:: Total revenues are significantly lower compared to previous periods, reflecting the transition of APHEXDA commercialization to Ayrmid.

Market Penetration Uncertainty:: With the commercialization of APHEXDA now under Ayrmid, BioLineRx lacks visibility into medium-term market penetration targets.

Clinical Development Risks:: The success of GLIX1 and motixafortide hinges on upcoming clinical trial results, which pose inherent risks in drug development.

5Notable Q&A Insights

Clinical Study Markers:: The company plans to collect pharmacokinetic (PK) data during the GLIX1 trial, with potential pharmacodynamic (PD) markers dependent on biopsy availability.

Manufacturing Capacity:: Current manufacturing capabilities are deemed sufficient for advancing GLIX1 through Phase IIa.

Market Interest in GBM Treatments:: For glioblastoma, a median overall survival improvement of approximately 2.5 months could attract interest from established pharmaceutical companies.

Financial Reporting of JV:: Expenses related to the JV will be consolidated into BioLineRx's financial statements, categorized primarily as R&D expenses. In conclusion, BioLineRx is positioning itself for future growth through strategic partnerships and innovative drug development, while also navigating challenges related to revenue generation and clinical trial outcomes.